Antares Pharma, Inc. (NASDAQ:ATRS) – Research analysts at Zacks Investment Research lifted their FY2017 earnings per share estimates for shares of Antares Pharma in a note issued to investors on Wednesday. Zacks Investment Research analyst J. Vandermosten now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.14) for the year, up from their prior estimate of ($0.16).
Several other analysts have also commented on ATRS. Raymond James Financial, Inc. started coverage on shares of Antares Pharma in a research note on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 target price for the company. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a research note on Friday, June 23rd. Chardan Capital began coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They set a “buy” rating and a $5.00 target price for the company. Vetr lowered shares of Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price target on the stock. in a report on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company’s stock. Antares Pharma presently has a consensus rating of “Buy” and an average target price of $3.83.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Weighs in on Antares Pharma, Inc.’s FY2017 Earnings (ATRS)” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2801595/zacks-investment-research-weighs-in-on-antares-pharma-inc-s-fy2017-earnings-atrs.html.
Antares Pharma (NASDAQ ATRS) traded up 1.7387% during mid-day trading on Friday, reaching $2.9199. 416,162 shares of the company’s stock traded hands. Antares Pharma has a 52-week low of $1.01 and a 52-week high of $3.37. The company has a 50-day moving average of $3.15 and a 200-day moving average of $2.76. The company’s market capitalization is $456.69 million.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The business had revenue of $13.42 million during the quarter, compared to analysts’ expectations of $12.99 million.
In other news, insider Fred M. Powell purchased 130,000 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were acquired at an average price of $2.79 per share, for a total transaction of $362,700.00. Following the completion of the acquisition, the insider now directly owns 331,434 shares of the company’s stock, valued at $924,700.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.60% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in ATRS. Alliancebernstein L.P. purchased a new stake in Antares Pharma during the second quarter worth about $119,000. Legal & General Group Plc bought a new position in Antares Pharma during the second quarter valued at $120,000. Credit Suisse AG bought a new position in Antares Pharma during the first quarter valued at $146,000. National Planning Corp raised its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares in the last quarter. Finally, KCG Holdings Inc. raised its position in Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares in the last quarter. Institutional investors and hedge funds own 31.70% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.